Annexon, Inc. (ANNX)
$3.67-4.18%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $601M
- Beta
- 1.33
- P/E (TTM)
- -3.16
- Short % float
- 18.23%
- Days to cover
- 8.9
- SI change
- -2.6%
- 1W
- -8.48%
- 1M
- -6.38%
- vs SPY 1W
- -7.50%
- vs SPY 1M
- -8.24%
Industry peers
FMP comparable companies · ranked by market cap
- ABVXSELLAbivax S.A.$6.5BCRISISQ 57$88.15+2.04%
- IMVTSELLImmunovant, Inc.$6.3BCRISISQ 25$30.47-2.82%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 15$24.63-0.55%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95+2.37%
- ALMSSELLAlumis Inc.$884MCRISISQ -1$7.16-7.62%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-2.59%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ANNX?
- LOPJLB’s latest quantitative signal on Annexon, Inc. (ANNX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANNX in?
- Annexon, Inc. (ANNX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Annexon, Inc. (ANNX) do?
- Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those s…